Sugi Predict

Sugi Predict / Compounds / SCHEMBL1107149

SCHEMBL1107149

SCHEMBL1107149

COC(=O)C(C)(C)c1ccc(C)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CNR2 P34972 3/20 0.57
▸ CNR1 P21554 1/20 0.57
▸ RAB9A P51151 4/20 0.47
▸ TP53 P04637 1/20 0.47
▸ NPC1 O15118 3/20 0.47
▸ MAPT P10636 1/20 0.47
▸ TDP1 Q9NUW8 1/20 0.47
▸ TSHR P16473 1/20 0.44
▸ KCNN4 O15554 1/20 0.44
▸ BRS3 P32247 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.43
▸ GAA P10253 1/20 0.43
▸ HDAC1 Q13547 1/20 0.42
▸ HDAC6 Q9UBN7 1/20 0.42
▸ HPGD P15428 1/20 0.39
▸ MMP13 P45452 1/20 0.39
▸ PLCG1 P19174 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8974321 0.91 CNR1 (0.54) CNR2CNR1RAB9AMAPTTDP1
SCHEMBL5877921 0.85 MAPT (0.50) CNR2CNR1RAB9ANPC1MAPT
SCHEMBL16327169 0.83 RAB9A (0.47) CNR2CNR1RAB9ATP53NPC1
SCHEMBL3573740 0.83 CNR1 (0.53) CNR2CNR1MAPTTSHRKCNN4
SCHEMBL23583000 0.82 MAPT (0.59) CNR2CNR1RAB9ATP53MAPT
SCHEMBL6825088 0.82 POLB (0.50) CNR2CNR1RAB9ANPC1MAPT
SCHEMBL8187459 0.82 MAPT (0.56) CNR2CNR1RAB9ATP53NPC1
SCHEMBL4673000 0.82 CNR1 (0.47) CNR2CNR1RAB9AMAPTTDP1
SCHEMBL6628 0.82 KMT2A (0.49) CNR2CNR1RAB9ANPC1MAPT
SCHEMBL1625320 0.82 CNR1 (0.47) CNR2CNR1KCNN4BRS3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof LG CHEM, LTD. (KR) 2026-05-26 — — US disclosed
US-12264169-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners (US) 2025-04-01 — — US disclosed
CN-115427405-B Tricyclic compounds, preparation method and medical application thereof 合肥医工医药股份有限公司 2024-09-24 — — CN disclosed
CN-110891951-B Compounds of formula (I) 谢菲尔德大学 2024-08-20 — — CN disclosed
EP-3628045-B1 COMPOUNDS UNIV SHEFFIELD (GB) 2024-07-03 — — EP disclosed
EP-4074701-B1 NOVEL AMIDE DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR, AND USE THEREOF LG CHEMICAL LTD (KR) 2023-12-13 — — EP disclosed
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-11-02 — — US disclosed
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-11-02 — — US disclosed
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 Tetra Discovery Partners, LLC 2023-11-02 — — US disclosed
US-11767334-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners, LLC (US) 2023-09-26 — — US disclosed
WO-2006027211-A1 2,4-SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS GLAXO GROUP LIMITED (GB) 2006-03-16 — — WO disclosed
WO-2006027211-A1 2,4-SUBSTITUTED PYRIMIDINES AS CYSTEINE PROTEASE INHIBITORS GLAXO GROUP LIMITED (GB) 2006-03-16 — — WO disclosed
US-20060052403-A1 Novel adenine compound and use thereof DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) 2006-03-09 — — US disclosed
EP-1550662-A1 NOVEL ADENINE COMPOUND AND USE THEREOF SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2005-07-06 — — EP disclosed
EP-1029851-B1 PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF MITSUBISHI PHARMA CORP (JP) 2005-04-20 — — EP disclosed
US-20030055064-A1 Piperazine compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION 2003-03-20 — — US disclosed
US-20030018034-A1 Piperazine compounds and medicinal use thereof MITSUBISHI PHARMA CORPORATION 2003-01-23 — — US disclosed
US-6455528-B1 TUMOR NECROSIS FACTOR ANTAGONIST AND/OR INTERLEUKIN PROMOTER; ANTIALLERGENS, ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASE TREATMENT MITSUBISHI PHARMA CORPORATION (JP) 2002-09-24 — — US disclosed
EP-1029851-A1 PIPERAZINE COMPOUNDS AND MEDICINAL USE THEREOF YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) 2000-08-23 — — EP disclosed
WO-1999015524-A1 THIAZOLE DERIVATIVES FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1999-04-01 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230348501-A1 HETEROARYL INHIBITORS OF PDE4 PDE4A, PDE4B, PDE4C CNR2 1911/4885CNR1 2453/4885RAB9A 1820/4885
US-20030055064-A1 Piperazine compounds and medicinal use thereof TNF, IL5, CCR10 CNR2 413/4885CNR1 399/4885RAB9A 1867/4885
US-20030018034-A1 Piperazine compounds and medicinal use thereof TNF, IL5, CCR10 CNR2 413/4885CNR1 420/4885RAB9A 1914/4885
US-11767334-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C CNR2 1911/4885CNR1 2453/4885RAB9A 1820/4885
US-12264169-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C CNR2 1911/4885CNR1 2453/4885RAB9A 1820/4885
US-20060052403-A1 Novel adenine compound and use thereof ADORA1, P2RY10, HRH4 CNR2 39/4885CNR1 23/4885RAB9A 1749/4885
US-12637440-B2 Amide derivative useful as diacylglycerol acyltransferase 2 inhibitor, and use thereof DGAT2, DGAT1, DLAT CNR2 229/4885CNR1 474/4885RAB9A 2009/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.